Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis

Nahrwold M, Weiß C, Bogner T, Mertink F, Conradi J, Sammet B, Palmisano R, Royo Gracia S, Preuße T, Sewald N (2013)
Journal of medicinal chemistry 56(5): 1853-1864.

Download
No fulltext has been uploaded. References only!
Journal Article | Original Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ; ; ; ;
Abstract / Notes
Tumor targeting anticancer drug conjugates that contain a tumor recognition motif (homing device) are of high current relevance. Cryptophycins, naturally occurring cytotoxic cyclo-depsipeptides, have been modified by total synthesis to provide analogues suitable for conjugation to peptide-based homing devices. An array of functionalized β(2)-amino acids was synthesized and incorporated into cryptophycins. All analogues proved to be highly active in the cytotoxicity assay using the human cervix carcinoma cell line KB-3-1 and its multidrug-resistant subclone KB-V1. Conformational analysis of cryptophycin-52 and two synthetic analogues was performed by NMR and MD methods to obtain information on the influence of the unit C configuration on the overall conformation. An azide-functionalized cryptophycin was connected by CuAAC to an alkyne-containing fluorescently labeled cyclic RGD-peptide as the homing device for internalization studies. Confocal fluorescence microscopy proved integrin-mediated internalization by endocytosis and final lysosomal localization of the cryptophycin prodrug.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Nahrwold M, Weiß C, Bogner T, et al. Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis. Journal of medicinal chemistry. 2013;56(5):1853-1864.
Nahrwold, M., Weiß, C., Bogner, T., Mertink, F., Conradi, J., Sammet, B., Palmisano, R., et al. (2013). Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis. Journal of medicinal chemistry, 56(5), 1853-1864. doi:10.1021/jm301346z
Nahrwold, M., Weiß, C., Bogner, T., Mertink, F., Conradi, J., Sammet, B., Palmisano, R., Royo Gracia, S., Preuße, T., and Sewald, N. (2013). Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis. Journal of medicinal chemistry 56, 1853-1864.
Nahrwold, M., et al., 2013. Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis. Journal of medicinal chemistry, 56(5), p 1853-1864.
M. Nahrwold, et al., “Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis”, Journal of medicinal chemistry, vol. 56, 2013, pp. 1853-1864.
Nahrwold, M., Weiß, C., Bogner, T., Mertink, F., Conradi, J., Sammet, B., Palmisano, R., Royo Gracia, S., Preuße, T., Sewald, N.: Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis. Journal of medicinal chemistry. 56, 1853-1864 (2013).
Nahrwold, Markus, Weiß, Christine, Bogner, Tobias, Mertink, Felix, Conradi, Jens, Sammet, Benedikt, Palmisano, Ralf, Royo Gracia, Soledad, Preuße, Thomas, and Sewald, Norbert. “Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis”. Journal of medicinal chemistry 56.5 (2013): 1853-1864.
This data publication is cited in the following publications:
This publication cites the following data publications:

13 Citations in Europe PMC

Data provided by Europe PubMed Central.

RGD-mediated delivery of small-molecule drugs.
Katsamakas S, Chatzisideri T, Thysiadis S, Sarli V., Future Med Chem 9(6), 2017
PMID: 28394627
Tumor Targeting with an isoDGR-Drug Conjugate.
Zanella S, Angerani S, Pina A, López Rivas P, Giannini C, Panzeri S, Arosio D, Caruso M, Gasparri F, Fraietta I, Albanese C, Marsiglio A, Pignataro L, Belvisi L, Piarulli U, Gennari C., Chemistry 23(33), 2017
PMID: 28449309
Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting.
Weiss C, Figueras E, Borbely AN, Sewald N., J Pept Sci 23(7-8), 2017
PMID: 28661555
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H, Lin Z, Arnst KE, Miller DD, Li W., Molecules 22(8), 2017
PMID: 28763044
Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin αV β3.
Raposo Moreira Dias A, Pina A, Dal Corso A, Arosio D, Belvisi L, Pignataro L, Caruso M, Gennari C., Chemistry 23(58), 2017
PMID: 28816404
The cryptophycins as potent payloads for antibody drug conjugates.
Verma VA, Pillow TH, DePalatis L, Li G, Phillips GL, Polson AG, Raab HE, Spencer S, Zheng B., Bioorg Med Chem Lett 25(4), 2015
PMID: 25613677
Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Dal Corso A, Caruso M, Belvisi L, Arosio D, Piarulli U, Albanese C, Gasparri F, Marsiglio A, Sola F, Troiani S, Valsasina B, Pignataro L, Donati D, Gennari C., Chemistry 21(18), 2015
PMID: 25784522
Design, characterization and cellular uptake studies of fluorescence-labeled prototypic cathepsin inhibitors.
Kohl F, Schmitz J, Furtmann N, Schulz-Fincke AC, Mertens MD, Küppers J, Benkhoff M, Tobiasch E, Bartz U, Bajorath J, Stirnberg M, Gütschow M., Org Biomol Chem 13(41), 2015
PMID: 26307943
Recent approaches for the synthesis of modified cryptophycins.
Weiss C, Sammet B, Sewald N., Nat Prod Rep 30(7), 2013
PMID: 23732943
Peptide conjugation via CuAAC 'click' chemistry.
Ahmad Fuaad AA, Azmi F, Skwarczynski M, Toth I., Molecules 18(11), 2013
PMID: 24284482

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 23387527
PubMed | Europe PMC

Search this title in

Google Scholar